


Infographic

Biosimilars


Infographic

2018-Q1 2023

Approved biosimilars by country




Approved biosimilars by molecule




Approved biosimilars by company




Approved biosimilars by disease (from Pharmaprojects)



Approved biosimilars by disease (from Trialtruve)



Leading pipeline programs by drug (from Pharmaprojects)



Indian Biosimilar Alliances

Deal Date	Deal Title	Deal Characteristics	Deal Type	Exclusivity of License
20/03/2023	Coya Enters Licensing Agreement for Dr. Reddy's Abatacept Biosimilar	R&D and Marketing	Licensing	Exclusive
03/11/2022	Intas Enters into an Exclusive License Agreement with Syna to commercialize LB-0702 in Global Markets	Marketing	Licensing	Exclusive
26/07/2022	Prestige Biopharma and Intas Pharmaceuticals Partner to Commercialize Bevacizumab Biosimilar	R&D and Marketing	Licensing	Exclusive
27/02/2022	Biocon Gains Option to Acquire Rights to Viatrix' Eylea Biosimilar; Later Exercises Option	R&D and Marketing	Licensing	-----
23/12/2021	TherameX Announces an Agreement with Enzene Biosciences for Tocilizumab Biosimilar	R&D and Marketing	Licensing	-----
08/12/2021	Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	Marketing	Licensing	Exclusive
02/03/2021	Cipla Gulf Expands Partnership with Alvotech in Australia and New Zealand	R&D and Marketing	Licensing	Exclusive
29/07/2019	Alvotech and Cipla Enter Partnership for AVT02 in Emerging Markets	Intra-Biotech Deal R&D and Marketing	Licensing	-----
14/01/2019	Bio-Thera Solutions Partners with Cipla to Market BAT1706	R&D and Marketing	Licensing	-----
01/07/2018	Mylan to sell Lupin's etanercept biosimilar	Royalty or Profit Split Marketing	Licensing	-----
21/06/2018	Henlius and Accord Pen Commercialization Agreement for HLX02	Royalty or Profit Split R&D and Marketing	Licensing	Exclusive